Synovus Financial Corp Crispr Therapeutics Ag Transaction History

Synovus Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$78.5 - $100.64 $1,570 - $2,012	-20 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$38.5 - $76.05 $8,855 - $17,491	-230 Reduced 92.0%	20 $1,000
Q1 2020 Apr 24, 2020	BUY	$33.68 - $62.53 $8,420 - $15,632	250 New	250 $11,000
Q4 2019 Feb 06, 2020	SELL	$36.68 - $73.13 $18,340 - $36,565	-500 Closed	0 $0
Q3 2018 Nov 01, 2018	BUY	$44.35 - $65.71 $22,175 - $32,855	500 New	500 $22,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.15B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Synovus Financial Corp with notifications on news.